Table 2 Incidence of thrombosis and bleeding after the index event

From: Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases

 

Events, n (%)

Incidence rate % pt-years (95% CI)

After a first thrombosis

(N=1500, total patient-years=6075)

Thrombotic events

348 (23.2%)

5.7 (5.1–6.4)

Major bleeding

77 (5.1%)

1.3 (1.0–1.6)

After first arterial thrombosis

(N=935, total patient-years=3907)

Thrombotic events

220 (23.5%)

5.6 (4.9–6.4)

Arterial thrombosis

170 (18.2%)

4.3 (3.7–5.0)

Venous thrombosis

50 (5.3%)

1.3 (0.9–1.7)

Major bleeding

44 (4.7%)

1.1 (0.8–1.5)

After a first venous thrombosis

(N=565, total patient-years=2168)

Thrombotic events

128 (22.6%)

5.9 (4.9–7.0)

Arterial thrombosis

36 (6.3%)

1.7 (1.2–2.3)

Venous thrombosis

92 (16.3%)

4.2 (3.4–5.2)

Major bleeding

33 (5.8%)

1.5 (1.0–2.1)